Core Viewpoint - The research indicates that succinate can maintain the fitness of CD8+ T cells to enhance antitumor immunity [4][7]. Group 1: Research Findings - The study reveals that in tumors lacking succinate dehydrogenase B (SDHB), the accumulation of succinate enhances the immune response mediated by CD8+ T cells [5]. - Continuous exposure to succinate promotes the survival of CD8+ T cells and helps generate and maintain their stem cell-like subsets [5]. - Succinate enhances mitochondrial adaptability through BNIP3-mediated mitophagy and promotes the expression of genes associated with stem cell characteristics via epigenetic regulation [5]. Group 2: Clinical Implications - CD8+ T cells treated with succinate exhibit superior long-term persistence and tumor control capabilities [5]. - In certain melanoma and gastric cancer patients receiving immune checkpoint blockade (ICB) therapy, succinate enrichment characteristics are associated with favorable clinical outcomes [5]. - The study highlights the potential of succinate supplementation in enhancing the efficacy of T cell immunotherapy [7]. Group 3: Mechanistic Insights - Succinate enhances CD8+ T cell antitumor activity and synergizes with immune checkpoint blockade therapy [5]. - The increased ratio of succinate to α-ketoglutarate promotes T cell stemness through epigenetic remodeling [5]. - Succinate characteristics can predict better clinical responses to CAR-T and immune checkpoint blockade therapies [5].